We are live on ! Find out more

Vivani Medical

VANI

Market cap $115M

1.27 USD

+0.02

1.6%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

1.29

+0.02

1.57%

1 day

1.6%

5 days

-9.29%

1 month

-8.63%

3 months

12.39%

6 months

11.4%

Year to date

0%

1 year

5.83%

5 years

-87.8%

10 years

-98.41%

About: Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.

Employees: 36

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 8.3%

Neutral 91.7%

Negative 0%

Vivani Medical Announces Participation in Upcoming Investor Conferences

ALAMEDA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants utilizing its proprietary NanoPortal™ technology, today announced its planned participation in two upcoming investor conferences:

Vivani Medical Announces Participation in Upcoming Investor Conferences

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026 Company entered into non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and Vivani's proprietary NanoPortal™ technology Completion of the Cortigent-ClearOne merger into Cortigent Holdings and initiation of trading on the Nasdaq exchange under ticker symbol CRGT anticipated in the third quarter of 2026 ALAMEDA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants utilizing its proprietary NanoPortal™ technology, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress.

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants.

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal

Vivani Medical NASDAQ: VANI said it is preparing to begin human testing of its semaglutide implant in August and highlighted a recently announced agreement with Novo Nordisk to evaluate the company's implant technology.

Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

ALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, biopharmaceutical company developing novel, miniature, GLP-1 drug implants with once- or twice-yearly administration, today announced that it will present at the Emerging Growth Conference on July 15, 2026.

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss

Vivani Medical believes a tiny implant placed under the skin could help address the biggest issue with blockbuster GLP-1s: keeping patients on treatment to maintain their weight loss. The biotech company is in the early stages of developing an experimental implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.

A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced the signing of a new agreement with Novo Nordisk to enable Novo Nordisk to evaluate NPM-139, the Company's semaglutide drug implant.

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

Vivani proposes to merge Cortigent, Inc. with a wholly owned subsidiary of ClearOne, Inc. (Nasdaq: CLRO), and change the listed company's name and ticker to Cortigent Holdings, Inc. (d/b/a Cortigent) and “CRGT”

Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical

SALT LAKE CITY--(BUSINESS WIRE)--ClearOne, Inc. (Nasdaq: CLRO) (“ClearOne”) announced today that it has entered into a definitive agreement and plan of merger (the “Agreement”) among its wholly-owned subsidiary (“MergerSub”), Vivani Medical, Inc. (Nasdaq: VANI; “Vivani”), and Cortigent, Inc. (“Cortigent”), a wholly-owned subsidiary of Vivani, pursuant to which Cortigent will become a wholly-owned subsidiary of ClearOne (the “Transaction”) upon consummation. In connection with the Transaction, C.

ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical

Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker

ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of August Moretti to its board of directors. Concurrent with this appointment, the Company announced the retirement of Dr. Dean Baker from the board.

Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker

See News Rankings

Price charts implemented using Lightweight Charts™